1 min read
Add as a preferred source on Google

Bristol Myers Squibb and Erasca Arrange Evaluation of Cancer Drug Pair

Erasca will supply ERAS-0015 for the evaluation, which focuses on pancreatic ductal adenocarcinoma.

Two unmarked vials stand beside a cell culture dish / TokenPost.ai
Two unmarked vials stand beside a cell culture dish / TokenPost.ai

Bristol Myers Squibb and Erasca have arranged to evaluate a drug combination of navlimetostat with ERAS-0015 for pancreatic ductal adenocarcinoma, the most prevalent pancreatic cancer type.

ERAS-0015 is a pan-RAS molecular glue, and Erasca will supply it for the evaluation. Navlimetostat is the other compound in the combination.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…